ArticleBritish journal of cancer1997
Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer--a predictor of tumour stage.
Article in British journal of cancer, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 93 citations in OpenAlex.
- Advances in Extracellular Matrix Metalloproteinases: Implications for Renal Cell Carcinoma Pathophysiology, Diagnostics, and Therapeutics.Medicines (Basel, Switzerland) · 2026Review
- The matrix in cancer.Nature reviews. Cancer · 2021Review
- The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.International journal of molecular sciences · 2020Review
- TIMPs: versatile extracellular regulators in cancer.Nature reviews. Cancer · 2017Review
- Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum.World journal of gastroenterology · 2016Review
- Reduced tissue inhibitor of metalloproteinase-2 expression is associated with advanced medullary thyroid carcinoma.Oncology letters · 2014Article
- Matrix metalloproteinases 2 and 9 immunoexpression in prostate carcinoma at the positive margin of radical prostatectomy specimens.Pathology research international · 2014Article
- Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation.The Journal of experimental medicine · 2013Article
- Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Review
- Matrix metalloproteinases and their inhibitors in canine mammary tumors.BMC veterinary research · 2011Article
- Overexpression of matrix metalloproteinase-21 is associated with poor overall survival of patients with colorectal cancer.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2011Article
- Immunohistochemically detected high expression of matrix metalloproteinase-2 as predictor of poor prognosis in Duke's B colon cancer.Croatian medical journal · 2008Article
- Suppression of local invasion of ameloblastoma by inhibition of matrix metalloproteinase-2 in vitro.BMC cancer · 2008Article
- Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.International journal of colorectal disease · 2007Article
- Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas.Molecular cancer · 2006Review
- Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer.British journal of cancer · 2006Article
- Modulation of monocyte matrix metalloproteinase-2 by breast adenocarcinoma cells.Breast cancer research : BCR · 2005Article
- Balance between activation and inhibition of matrix metalloproteinase-2 (MMP-2) is altered in colorectal tumors compared to normal colonic epithelium.Digestive diseases and sciences · 2002Article
- Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer.British journal of cancer · 2002Article
- Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma.British journal of cancer · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to investigate whether immunohistochemical staining patterns of tissue inhibitor of metalloproteinases TIMP-2 and matrix metalloproteinases MMP-2 and MMP-9 can be predictors of tumour stage and survival time in colorectal cancer. Frozen tumour sections from 212 patients operated on between January 1987 and November 1990 were investigated. Three mouse monoclonal antibodies--T2-101 against TIMP-2, CA-4001 against MMP-2 and GE-213 against MMP-9--were used. Positive expression of TIMP-2 (a) in basement membranes and (b) diffusely in stroma with (c) subglandular enhancement was found significantly (P < 0.01, P < 0.05, P < 0.05) more often in localized tumours than in tumours with regional or distant metastases. Neither pattern correlated with tumour differentiation. Patterns (a) and (c) correlated with longer survival time (P < 0.05); (b) reached near significance (P < 0.07). When the survival analyses were restricted to potentially cured patients, neither pattern could foretell death from cancer. Positive expression of MMP-2 in tumour epithelium and of MMP-9 in tumour-infiltrating macrophages were both independent of tumour stage and were without correlation with survival time. A large number of MMP-9-positive macrophages correlated (P < 0.05) with poor tumour differentiation, whereas weak or absent epithelial MMP-2 staining reached near significance (P < 0.08). Exploration of TIMP-2 expression is valuable for the discrimination between macroscopically localized and metastatic colorectal cancer, but it cannot predict which of the potentially cured patients are likely to have micrometastases. MMP-2 and MMP-9 stainings are of minor value in staging and prognostic prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.